In Washington’s debate over enacting steep funding cuts to Medicaid, words are a central battleground. Many Republican lawmakers and conservative policy officials who want to scale back the joint state-federal health program are using charged language to describe it. Language experts and advocates for Medicaid enrollees say their word choice is misleading and aims to…
Casi un año después que la administración Biden diera luz verde a Florida para convertirse en el primer estado en importar medicamentos recetados más baratos de Canadá —un objetivo de muchos políticos de todas las tendencias, incluido el presidente electo Donald Trump— el programa aún no ha comenzado. El gobernador de Florida, Ron DeSantis, celebró…
By MIKE MAGEE When Andrew Jameton, a Nursing Professor at the Department of Mental Health and Community Nursing at UCSF in 1984 published “Nursing Practice: The Ethical Issues”, the term “Moral Distress” was a novel term in clinical health care. It focused primarily on “care that they were expected to provide but ethically opposed.” Over…
This issue brief examines California’s Medicaid work requirement implementation plans to provide initial insight into how California is preparing to implement work requirements amid projected state budget shortfalls and changes in the 2025 reconciliation law.
Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent. The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis…
A pioneering program is improving patient outcomes in and outside hospitals
The core challenge for leadership is no longer merely managing direct vendors; it’s the cascading risk of the “nth-party” supplier. The post Compliance: Why Your Vendor’s Vendor is a Growth Risk appeared first on MedCity News.
In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by Regeneron Pharmaceuticals and Bayer. The post Ocular Therapeutix Eyes FDA Filing After…
The Host Julie Rovner KFF Health News @jrovner Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to…
Healthcare organizations face challenges with siloed data, causing repeated paperwork